Background: Tirapazamine (TPZ), a new anti-cancer drug activated to a toxic free radical under hypoxic conditions, produces a tumor specific potentiation of cell kill by cisplatin. In the present study we discuss the mechanism and clinical potential of this effect, as well as investigate the influence of p53 mutations on the activity of TPZ.
Introduction
Tirapazamine (3-amino-l,2,4-benzotriazine 1,4-dioxide, SR 4233, TPZ) is a new anti-cancer drug with specific activity towards cells at low oxygen tensions [1, 2] . This preferential toxicity towards hypoxic cells has been demonstrated by a number of different laboratories with many different cell lines of rodent and human origin. The hypoxic cytotoxicity ratio (ratio of drug concentrations under aerobic to hypoxic conditions to give the same level of cell kill) is typically in the range of 50-150. This is much larger than that found for the prototypic bioreductive drug mitomycin C for which values of 1 (no differential toxicity) to 5 have been reported [3, 4] . Figure 1 shows typical data for the killing of cells under aerobic and hypoxic conditions exposed to TPZ for 1.5 hours.
The mechanism for the preferential toxicity of TPZ towards hypoxic cells is a result of an enzymatic reduction that adds an electron to the TPZ molecule forming a highly reactive radical [2] . This radical causes cell killing by producing DNA damage leading to chromosome aberrations [5] . However, in the presence of oxygen, the radical is 'back oxidized' to the nontoxic parent with a concomitant generation of superoxide radicals [6] . Because of the high reactivity of the TPZ radical (and hence its limited diffusion capability), as well as the similarity of the chromosome breaks produced by TPZ to those induced by densely ionizing radiation, we have suggested that the activating reductase(s) must be close to DNA, thereby producing high local concentrations of the radical [2] . Our laboratory has recently obtained support for this hypothesis by showing that DNA damage occurs only from TPZ metabolism within the nucleus [7] . A diagrammatical representation of TPZ metabolism close to DNA producing DNA damage is shown in Figure 2 .
TPZ combined with platinum based chemotherapy: A tumor specific synergistic interaction
Because of the demonstration in pre-clinical studies with transplanted tumors that hypoxic cells in these tumors are resistant to killing by cisplatin [8] , we reasoned that TPZ with cisplatin would be an effective combination based on the complementary cytotoxicity of the two agents. When this combination was tested in transplanted tumors, we indeed found that the combination was highly synergistic unless the two drugs were given at the same time. Figure 3 shows the data for cell Figure 1 . Diagrammatical representation of a reductase mediated metabolism of tirapazamine (TPZ) to its active radical. This radical produces DNA single-strand breaks (ssb's) and double-strand breaks (dsb's) leading to hypoxic cytotoxicity. In the presence of oxygen, the TPZ radical is back-oxidized to the parent drug with concomitant production of superoxide radical, which probably is responsible for the aerobic toxicity of the drug. From Brown & Giaccia [34] . survival of the RIF 1 tumor treated in vivo with TPZ and cisplatin with different time periods between the two injections. These data demonstrate that, whereas the two agents given at the same time produce additive cytotoxicity, when TPZ is given before cisplatin, there is a highly synergistic interaction of the two agents. Despite this enhancement of tumor cell kill, we have shown that there is no change in the systemic toxicity of cisplatin when TPZ is combined with cisplatin [9] . Thus, the synergistic interaction of TPZ with cisplatin is tumor specific and therefore represents a therapeutic gain over cisplatin alone. We, and others, have obtained similar TPZ synergy with carboplatin, with combinations of TPZ and cisplatin with either etoposide or navelbine [10] , and with combinations of TPZ with carboplatin and taxol [11] , or oxaliplatin and Taxol [12] . These preclinical studies have formed the basis for extensive clinical testing of TPZ combined with cisplatin, particularly in advanced non-small-cell lung cancer (NSCLC). To date phase I and II clinical studies have confirmed both the increased anti-tumor activity of TPZ combined with cisplatin compared to historical controls of cisplatin only, as well as the absence of any increased systemic toxicity of cisplatin [13] [14] [15] . Recently, results of an international randomized phase III study of TPZ plus cisplatin versus cisplatin alone in stage IIIB and IV NSCLC demonstrated a significant survival advantage of the combination versus cisplatin alone [16] . These clinical studies, therefore, confirm the tumor specific synergy between TPZ and cisplatin and suggest that TPZ may prove to be an effective addition to chemotherapy regimens of solid tumors that contain platinum based anti-cancer drugs.
Mechanism of the tumor specific potentiation of cisplatin by TPZ
Although the original hypothesis that cisplatin and TPZ would be an effective combination in tumors based on their complementary cytotoxicity for aerobic and hypoxic cells respectively, this cannot account for all of the interaction. We have shown, for example, that RIF 1 cells treated in vitro with TPZ under hypoxic conditions are more sensitive to killing by a subsequent dose of cisplatin [9] . We have now performed additional in vitro studies, which have confirmed this increased sensitization of cells by pre-treatment by TPZ under hypoxic conditions [17] . In particular, we have shown that when the two drugs are given at the same time, there is only additive cytotoxicity, whereas when TPZ is given prior to the cisplatin, the interaction is synergistic, as was shown for tumors in vivo. We observed this synergistic interaction with human non-small-cell lung cancer cells, with NIH3T3 mouse cells, and with hamster CHO cells. We have also shown that this interaction depends on the TPZ exposure being under hypoxic conditions; there is absolutely no interaction when the TPZ is given under aerobic conditions. Figure 4 . Clonogenic cell survival of E1A and Hras transformed mouse embryo fibroblasts (MEFs) from p53 wild-type (p53*'*) and p53 knockout (p53~'~) mice. The cells were exposed to TPZ under hypoxia for one hour and the survival measured by clonogenic assay.
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In an attempt to understand the mechanism for this synergy, we have found that the interaction does not occur in cells that are deficient in DNA cross-link repair, thereby implicating this repair process in the mechanism of the interaction. Indeed, we have shown that cells pretreated with TPZ under hypoxic conditions are more susceptible to cisplatin induced DNA interstrand cross-links [17] .
Given the similarity of the schedule dependence of the in vitro and in vivo results, it seems likely that most, if not all, of the interaction is a result of this cellular phenomenon rather than as a result of complementary cytotoxicity between TPZ and cisplatin in the tumor. The absolute requirement for hypoxia, however, is the basis for the tumor selectivity. The fact that most human tumors have median oxygen levels well below those of normal tissues [18] is the basis for the expectation that this tumor specific interaction will occur in the majority of human tumors.
TPZ cytotoxicity is independent olp53 status
Since the p53 tumor suppressor gene is mutated in more than half of all solid tumors including NSCLC [19] , and mutations in p53 are associated with significantly worse prognosis for these tumors [20] , it is pertinent to ask whether cells with mutated p53 are more resistant to TPZ, as has been suggested for many anti-cancer agents [21] . We have tested for this in two different ways. First, we have measured the surviving fraction using a clonogenic assay for mouse embryo fibroblasts (MEF's) transfected with the dominant oncogenes Ela and Uras. The mouse embryo fibroblasts were obtained from wildtype (p53
) and p53 knockout (p53~'~) mice. These samep53~'~ MEF's have been shown to be resistant to several anti-cancer drugs, both as cells in vitro [22] and as tumors growing in immune suppressed mice [23] . Figure 4 shows the results of this experiment and demonstrates that by clonogenic survival, the p53 +/+ and p53~'~ cells have essentially the same sensitivity to a one-hour treatment of various concentrations of TPZ under hypoxia.
In the second series of experiments, we have performed a similar study with the NSCLC cell lines taken from the NCI panel of 60 cell lines that is used to screen anti-cancer agents. Nine of these eleven cell lines were easily cloned in vitro, and their sensitivity by clonogenic assay to various concentrations of TPZ under hypoxia is show in Figure 5 . The p53 status of these cell lines has recently been published [24] , and seven of the nine have mutant p53. It can be seen from Figure 5 , however, that the two cell lines with wild-type p53 fall within the range of the sensitivities to TPZ of the cells with mutant p53. Again, therefore, these data support the view that the cytotoxicity of TPZ under hypoxia is independent ofp53 status.
Although these data do not address the question of whether the interaction of TPZ with cisplatin is dependent upon p53 status, the fact that cells with mutant p53 have been shown to be more sensitive to cisplatin [25] suggests that there is little or no basis for expecting that NSCLC with mutated p53 would be refractory to the combination of cisplatin with TPZ.
Clinical potential
Tirapazamine (TPZ) is the first drug to enter clinical practice that exploits a unique feature of solid tumors, namely their low oxygen tension. The drug is inactive until it is metabolized to a damaging radical, a process that only occurs at oxygen tensions lower than those found in normal tissues but well within the range of those found in a variety of human solid tumors, including brain [26] , head and neck [27] , lung [28] , breast [29] , cervix [30] , anal canal [31] , and soft tissue sarcomas [32] . All of these data show that the median oxygenation of these human tumors is considerably less than that of normal tissues. It is this lower oxygen level that is responsible for the preferential metabolism of TPZ in tumors and, as our data indicate, is responsible for the tumor specific synergy between TPZ and fractionated radiation [33] and platinum based chemotherapy [9, 10] . In terms of the interaction of TPZ with cisplatin, clinical trials have now shown that both response rates and survival times of patients with advanced non-small lung cancer can be significantly increased when TPZ is added to standard cisplatin based chemotherapy. Since preclinical studies have also shown that TPZ is synergistic with cisplatin, carboplatin and oxaliplatin either alone or combined with etoposide, navelbine or with Taxol, this suggests that the addition of TPZ to these combinations is likely to prove more effective than any two drug combinations presently being employed with this disease.
